The discovery and development of immune checkpoint inhibitors has revolutionized the treatment of certain cancers.Yet, despite these advances, putative biomarker identification, efficacy, and drug resistance still pose significant therapeutic challenges. In this webinar, leaders in immuno-oncology — Elaine Mardis (The Ohio State University) and Jedd Wolchok (Memorial Sloan Kettering Cancer Center) — survey the landscape of research, revealing new approaches for harnessing the potential of this transformative therapeutic.
